Pneumococcal Vaccine Candidate MVX01

A pneumolysin protein fused with Choline binding protein A epitopes creates our serotype-independent, dual-antigen vaccine to combat pneumococcal disease

C. difficile Vaccine Candidate MVX02

C. difficile infections result in 14,000 deaths per year in the United States.  Matrivax is targeting both  the pathogen and the toxoids in our unique vaccine.

Applying breakthrough science to develop innovative, clinically-impactful vaccines for people in need around the world

1. WHO, 2000;   2. WHO, 2005;   3. CDC, 2019

Contact Us

650 Albany Street, Suite 117, Boston, MA 02118  |  Tel: 617-358-7640

© 2020 Matrivax Research and Development Corporation

650 Albany Street, Suite 117, Boston, MA 02118